Prot #20190135: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Project: Research project

Project Details

StatusActive
Effective start/end date2/23/212/23/27

Funding

  • Greenphire, Inc. ((OE) Prot #20190135 // (OE) Prot #20190135)
  • Amgen, Inc. ((OE) Prot #20190135 // (OE) Prot #20190135)